Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: Role of bystander suppression

Therapeutic Apheresis

Volumn 2, Issue 2, 1998, Pages 109-114

  Noguchi, Mitsunori ^a   Hiwatashi, Nobuo ^a   Hayakawa, Tomohiko ^a   Toyota, Takayoshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bystander suppression; Inflammatory bowel disease; Interleukin 4; Leukocytapheresis; Leukocyte migration; T helper 2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; LECTIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD FILTER; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENTERITIS; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; LEUKAPHERESIS; LEUKOCYTE; LEUKOCYTE MIGRATION; LYMPHOCYTE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0031862224     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1998.tb00086.x     Document Type: Article

References (25)

1. Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, Amano K, Wada M, Tanida N, Satomi M, Shimoyama T. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995;30:322-9.
2. Lerebours E, Bussel A, Modigliani R, Bastit D, Florent C, Rabran C, Rene E, Soule J, Groupe D'Etudes Therapeutiques des Affections Inflammatoires Digestives. Treatment of Crohn's disease by lymphocyte apheresis: A randomised controlled trial. Gastroenterology 1994;107:357-61.
3. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: Pilot trial in multiple sclerosis. Lancet 1995;346:807-8.
4. Weiner HL, Freidman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham PE, Hafler DA. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809-37.
5. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-8.
6. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
7. Sawada K, Malchesky PS, Nosé Y. Available removal system: State of the art. In: Nydegger UE, ed. Therapeutic hemapheresis in the 1990s No. 57, Current studies in hematology and blood transfusion. Basel: Karger, 1990:51-113.
8. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Enhanced interferon-γ production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. J Gastroenterol 1995;30(S8):52-5.
9. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, Maino VC. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995;86:1408-19.
10. Rocken M, Rache EM, Shevach EM. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today 1996;17:225-31.
11. Shimada A, Rohane P, Fathman CG, Charlton B. Pathogenic and protective roles of CD45RB low CD4+ cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Diabetes 1996;45:71-8.
12. Tada T, Takemori T, Okumura K, Nonaka M, Tokuhisa T. Two distinct types of helper T cells involved in the secondary antibody response: Independent and synergistic effects of Ia-and Ia+ helper T cells. J Exp Med 1978;147:446-58.
13. Stekel DJ, Parker CE, Nowak A. A model of lymphocyte recirculation. Immunol Today 1997;18:216-20.
14. Westermann J, Pabst R. How organ-specific is the migration of naive and memory T cells? Immunol Today 1996;17: 278-82.
15. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-6.
16. Segal AW, Ensell J, Munro JA, Sarner M. Indium-111 tagged leucocytes in the diagnosis of inflammatory bowel disease. Lancet 1981;2:230-2.
17. Pullman WE, Sullivan PJ, Barratt PJ, Lising J, Booth JA, Doe WF. Assessment of inflammatory bowel disease activity by technetium 99m phagocyte scanning. Gastroenterology 1988; 95:989-96.
18. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255-60.
19. Duchmann R, Kaiser I, Hermann E, Mayet W, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995;102:448-55.
20. Khoo UY, Proctor IE, Macpherson AJS. CD4+ T cell down-regulation in human intestinal mucosa: Evidence for intestinal tolerance to luminal bacterial antigens. J Immunol 1997;158: 3626-34.
21. Liu ZX, Sugawara S, Hiwatashi N, Noguchi M, Rikiishi H, Kumagai K, Toyota T. Accessory cell function of a human colonic epithelial cell line HT-29 for bacterial superantigens. Clin Exp Immunol 1997;108:384-91.
22. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-5.
23. Blumberg RS, Terhorst C, Bleicher P, Allan C, McDermott FV, Landau SB, Trier J, Balk SP. Expression of nonpolymorphic MHC class I-like molecule, CD1d, by human intestinal epithelial cells. J Immunol 1991;147:2518-24.
24. Kawanishi T, Tsuda H. Therapeutic lymphocytapheresis in rheumatoid arthritis. Comparison of leukocyte removal filter method and centrifugal method. Jpn J Artif Organs 1994;23(2):506-10.
25. Antel JP, Becher B, Owens T. Immunotherapy for multiple sclerosis: From theory to practice. Nat Med 1996;2:1074-5.